Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment. - Wikidata - wikimedia - TriplyDB

Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment.

Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment.

http://www.wikidata.org/entity/Q36820491

about

The Mechanism of and Preventive Therapy for Stroke in Patients with Atrial Fibrillation EHRA/HRS/APHRS/SOLAECE expert consensus on Atrial cardiomyopathies: Definition, characterisation, and clinical implication.Prediction of New-Onset and Recurrent Atrial Fibrillation by Complete Blood Count Tests: A Comprehensive Systematic Review with Meta-Analysis.Atrial fibrillation and the risk of myocardial infarction.Increased tissue plasminogen activator levels in patients with nonvalvular atrial fibrillation Atrial fibrillation and stroke: what we know, what's new, and what we should do now.Platelet dysfunction in thrombosis patients treated with vitamin K antagonists and recurrent bleeding.Diagnostic value of D-dimer and antithrombin-III levels in predicting prosthetic heart valve thrombosis.The effects of magnesium on the course of atrial fibrillation and coagulation in patients with atrial fibrillation undergoing mitral valve annuloplasty Fibrinogen: biochemistry, epidemiology and determinants.Plasma von Willebrand factor, soluble thrombomodulin, and fibrin D-dimer concentrations in acute onset non-rheumatic atrial fibrillation Association of hemostatic markers with atrial fibrillation: a meta-analysis and meta-regression.Prevention of venous thromboembolism after stroke.Atrial Fibrillation and Risk of ST-Segment-Elevation Versus Non-ST-Segment-Elevation Myocardial Infarction: The Atherosclerosis Risk in Communities (ARIC) Study Effects of blood pressure on the prothrombotic risk in 1235 patients with non-valvular atrial fibrillation P-selectin inhibition therapeutically promotes thrombus resolution and prevents vein wall fibrosis better than enoxaparin and an inhibitor to von Willebrand factor.Embolic Stroke Diagnosed by Elevated D-Dimer in a Patient With Negative TEE for Cardioembolic Source Effect of heart rate control on coagulation status in patients of rheumatic mitral stenosis with atrial fibrillation--A pilot study von Willebrand factor and its relevance to cardiovascular disorders Haemostatic and haemodynamic abnormalities associated with left atrial thrombosis in non-rheumatic atrial fibrillation.Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban Mechanisms And Management Of Thrombo-Embolism In Atrial Fibrillation Cardioembolic stroke in atrial fibrillation-rationale for preventive closure of the left atrial appendage.Von Willebrand Factor Plasma Levels Variability In Nonvalvular Atrial Fibrillation.Stroke and Death Prediction with the Impact of Vascular Disease in Patients with Atrial Fibrillation.Effect of Oral Anticoagulant Therapy on Coagulation Activity and Inflammatory Markers in Patients with Atrial Fibrillation Undergoing Ablation: A Randomized Comparison between Dabigatran and Warfarin.Assessment of endothelial (dys)function in atrial fibrillation.Fluctuations in coagulation activity among patients with atrial fibrillation who are stably anticoagulated.Early Changes in the Antithrombin and Thrombin-Antithrombin Complex in Patients With Paroxysmal Atrial Fibrillation.Genetic polymorphisms and atrial fibrillation: Insights into the prothrombotic state and thromboembolic risk.Clopidogrel hydrogen sulphate for atrial fibrillation.Biomarkers in atrial fibrillation: a clinical review.Hypercoagulability, D-dimer and atrial fibrillation: an overview of biological and clinical evidence.Intracardiac thrombus formation in cardiac impairment: the role of anticoagulant therapy Platelets Cellular and Functional Characteristics in Patients with Atrial Fibrillation: A Comprehensive Meta-Analysis and Systematic Review.Predictive Role of Coagulation, Fibrinolytic, and Endothelial Markers in Patients with Atrial Fibrillation, Stroke, and Thromboembolism: A Meta-Analysis, Meta-Regression, and Systematic Review.Prognostic role of plasma von Willebrand factor and soluble E-selectin levels for future cardiovascular events in a 'real-world' community cohort of patients with atrial fibrillation.Hypercoagulability and haemodynamic abnormalities in atrial fibrillation.Does von Willebrand factor improve the predictive ability of current risk stratification scores in patients with atrial fibrillation?Albumin level and stroke. Potential association between lower albumin level and cardioembolic aetiology.

P2860

Q26747263-3C4C1D49-BAD5-4B18-B288-66A346C89314 Q30375302-2CFCCBE7-2A9F-44F1-9F84-5C2EF51EF249 Q33712583-A86326C2-6A09-4D19-9D47-3651C55B4285 Q33970602-E07F78EF-4BE4-46E8-B964-491AB50C29A0 Q34025555-AB1025CE-0FC6-4CE8-8141-C2E80F87B1F7 Q34025564-F22C646E-91F6-4680-9ACA-6FC441007A23 Q34749456-101D80A8-E949-42E1-A87E-40C348B49F3A Q34796486-DFD31F46-1BA9-41ED-9033-8BB1151EAF7B Q35406672-4B46F408-E66D-4F54-9F97-F7CAB500C7CD Q35538771-D63821BB-6E9E-42D0-88D7-2B7916502FBB Q35582996-9956AE01-1F1F-4E0B-964A-90AFD9280C70 Q35605552-F34ABBCE-6A7F-48D2-908B-701614FD4955 Q35610118-8CB421A4-C096-4474-99B1-EC12075B1D65 Q35661109-D5D9FBD2-0884-4CC5-9A41-EC04DFE22D01 Q35773343-4887D388-9BD2-4C71-9193-CEE1CAECFE29 Q35811705-3B4A3B7D-8389-4BC6-BE28-B76E93F0334F Q35927655-B38F89DB-A1B1-4D94-B79C-B575F7117604 Q36396662-7C0B9BF2-A426-40DE-8381-F66A7DFC7DDA Q36825948-79F5142F-FC00-4CD3-9717-36ED37A1A304 Q36843189-183677D5-4A03-4D97-A55B-B2F40BCAB201 Q37085638-17B17D96-8BC8-496E-AC69-BEE1748203D8 Q37115524-E22F821C-73B7-4D25-AA34-4A3078E997CE Q37464600-B2DFC425-2C3D-4412-8019-702EA5F91816 Q37468947-BB69EA1E-AED0-4D87-901C-AD99B22FFE95 Q37495877-272A5960-8040-46E7-8234-81910FCD9F9A Q37576987-AD779DA1-2967-40DC-98EA-FD338CF1F19F Q37587835-F509EBC5-D3A6-44A5-A6DF-384BE85F9E6A Q37608475-F6F6800F-10EC-478C-B49D-91778430F8E0 Q37629177-FC23C524-D593-4E6F-933B-82CD66353011 Q37777419-31575813-0037-48DD-B0A1-421BF6BD7733 Q37887815-5AC33746-E20F-44AF-BF4B-AC0EBD0210E2 Q38079565-87D98C70-C5B7-474A-BDF7-ED8FBE4C7169 Q38215163-24C1A168-3703-47E4-9116-7C4A667BDBCD Q38646824-EEB4E89F-907C-4B06-9F76-9DFDA77E4805 Q39182923-C10F0F15-96E5-4F71-B475-E1EEB1527E87 Q39209674-E32D634C-A7F1-418A-84DC-0B8287752237 Q39364345-E1D120DD-C471-4C6F-994E-D80BE6E1842A Q41343151-CC174293-C530-4D88-A6A3-7631FB0C8971 Q41857087-3D47EE3D-9123-438C-A0B3-E1B67212C324 Q44749615-086951B7-4871-4A03-8EFE-3BC155363B06

P2860

Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment.

http://www.wikidata.org/entity/Q36820491

description

1995 nî lūn-bûn

@nan

1995年の論文

@ja

1995年論文

@yue

1995年論文

@zh-hant

1995年論文

@zh-hk

1995年論文

@zh-mo

1995年論文

@zh-tw

1995年论文

@wuu

1995年论文

@zh

1995年论文

@zh-cn

name

Increased markers of thromboge ...... effects of warfarin treatment.

@en

type

label

Increased markers of thromboge ...... effects of warfarin treatment.

@en

prefLabel

Increased markers of thromboge ...... effects of warfarin treatment.

@en

P1433

Q36820491-DFD8E382-8E24-4BF1-B9B7-01FAA968E6D0

P1476

Q36820491-DCFC20D0-981A-4AB1-B4C7-A804E86099B5

P2093

Q36820491-81316EB9-E094-4A22-AD49-CEF4EB0ECA84

Q36820491-869018EB-FCFE-40AD-BB60-35B32F5AB145

Q36820491-AC283DCF-3821-4C0A-ADEB-830FBC1BFC2B

Q36820491-ADECD2FB-04C2-4AC1-BA37-AC42A4E492C5

P2860

Q36820491-5C6E698B-1B51-41CE-9411-2C80D5A10984

Q36820491-87D5365B-ABED-43A4-B385-0A7ED326458F

Q36820491-9DF06C65-2C04-41AE-9CCA-F57C8068CC3D

Q36820491-C5FF00B5-AC75-41F3-BDA2-3700885C146A

Q36820491-E23EF83B-F001-46C7-A54F-5CD0B6F247C8

Q36820491-E9C51CC4-02B9-4060-96A9-D84E4FB79B17

Q36820491-F2381EA1-4BB0-46BC-BA7B-368605A595A3

Q36820491-FF2053A8-79DB-4162-B9A7-4039185A38BF

P304

Q36820491-093D91F4-35C4-42CC-B2B1-59D5F8D92A64

P31

Q36820491-32027127-478C-4A56-9B3C-2EEF3CEA0885

P356

Q36820491-F0A7C35F-D072-41DD-BBBB-3C2678090C8A

P433

Q36820491-CE920CB5-D437-4AF4-BEF7-B9D4578E4E75

P478

Q36820491-50AD340F-4EE0-42E2-A294-E7C353E48626

P577

Q36820491-89AC9586-14DF-4A92-BA1F-B892193A9139

P5875

Q36820491-241F976F-6AC2-42D1-8EDA-86E87AC6A941

P698

Q36820491-679325D4-759C-4823-8C19-C37AA321264D

P921

Q36820491-41900F14-D57A-4955-83DC-5AA656ADEF8F

P932

Q36820491-7DC8A64E-348A-4BCA-8190-691AD23C986F

P356

P1433

British heart journal

P1476

Increased markers of thromboge ...... effects of warfarin treatment.

@en

P2093

Dunn FG

http://www.w3.org/2001/XMLSchema#string

Lip GY

http://www.w3.org/2001/XMLSchema#string

Lowe GD

http://www.w3.org/2001/XMLSchema#string

Rumley A

http://www.w3.org/2001/XMLSchema#string

P2860

von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death.

Atrial enlargement as a consequence of atrial fibrillation. A prospective echocardiographic study.

Regulation of fibrinogen synthesis by plasmin-derived fragments of fibrinogen and fibrin: an indirect feedback pathway.

Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements

Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature.

Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease.

Antithrombotic treatment and atrial fibrillation.

Platelet function tests in thrombotic cerebrovascular disorders.

P304

527-533

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/HRT.73.6.527

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

73

http://www.w3.org/2001/XMLSchema#string

P577

1995-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

15573498

http://www.w3.org/2001/XMLSchema#string

P698

7626351

http://www.w3.org/2001/XMLSchema#string

P921

atrial fibrillation

P932

483914

http://www.w3.org/2001/XMLSchema#string